Gentian Diagnostics ASA

Earnings Release • Feb 15, 2017

Q4 2016 Financial Report and Preliminary Annual Report

Q4 2016 Financial Report and Preliminary Annual Report

Gentian Diagnostics AS announces its results for the fourth

quarter and preliminary results for the full year of 2016.

The highlights of the quarter include:

- Total revenues of MNOK 31.0 for 2016

- Plasma calprotectin test on track to be launched in the

second half of 2017

- Continued progress in all development projects

- Gentian Diagnostics was listed on Merkur Market in

December 2016

- Acquisition of PreTect AS completed in October 2016

- Successful completion of private placement of MNOK 100

after the balance sheet date

Please find the report for the fourth quarter enclosed. The

report will also be made available on www.gentian.no.

For further information, please contact:

Bård Sundrehagen

CEO, Gentian Diagnostics

E-mail: Bard.sundrehagen@gentian.no

Cell Phone: +47 924 14 117